Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2022 Earnings Call Transcript
Operator: Good afternoon and welcome ladies and gentlemen to Cytokinetics' Fourth Quarter 2022 Conference Call.
Posts Tagged ‘NASDAQ:CYTK’
Is Cytokinetics (CYTK) a Good Long-Term Investment?
Baron Funds, an investment management company, released its “Baron Health Care Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here.
Is Cytokinetics, Inc. (CYTK) Going to Burn These Hedge Funds?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market...
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy...
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need ...
Is CYTK Stock A Buy or Sell?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
10 Best Biotech Stocks to Invest In According To Billionaire Biotech Hedge Fund
In this article, we will present the 10 best stocks to invest in according to the billionaire biotech hedge fund manager Joe Edelman.
Top 10 Healthcare Stocks To Buy for the Future
Small- and mid-cap biotech and pharmaceutical companies represent some of the most compelling gambles available on the market.
Hedge Funds Keep Buying Cytokinetics, Inc. (CYTK)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Did Hedge Funds Make The Right Call On Cytokinetics, Inc. (CYTK) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Hedge Funds Have Never Been This Bullish On Cytokinetics, Inc. (CYTK)
In this article you are going to find out whether hedge funds think Cytokinetics, Inc. (NASDAQ:CYTK) is a good investment right now.
Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy?
We at Insider Monkey have gone over 752 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio...
Here is What Hedge Funds Really Think About Cytokinetics, Incorporated (CYTK)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Hedge Fund and Insider Trading News: Michael Platt, Warren Buffett, Balyasny Asset Management, AQR Capital, Aspen Group Inc (ASPU), W&T Offshore, Inc. (WTI), and More
BOSTON (Reuters) - Balyasny Asset Management, a Chicago-based hedge fund that shed $4 billion in assets last year and cut 20% of its staff, was back in positive territory for ...
Did Hedge Funds Drop The Ball On Cytokinetics, Inc. (CYTK) ?
Hedge fund interest in Cytokinetics, Inc. (NASDAQ:CYTK) shares was flat at the end of last quarter and it wasn't that high to begin with. This is usually a negative indicator.
Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK)
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
13G Filing: Biotechnology Value Fund LP and Cytokinetics Inc (CYTK)
Please follow Biotechnology Value Fund LP (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update...
13G Filing: Biotechnology Value Fund LP and Cytokinetics Inc (CYTK)
You can access the original SEC filing by clicking here.
Here’s What You Should Know About The Finance World Today
"U.S. stocks retreated on Tuesday as a spate of tepid corporate earnings weighed on the broader market.
Cytokinetics, Inc. (CYTK) Hedge Funds Are Snapping Up
Looking for high-potential stocks? Just follow the big players within the hedge fund industry.
Cytokinetics Inc (CYTK): Mark Lampert’s Biotechnology Value Fund Loads Up On More Shares
Mark Lampert's Biotechnology Value Fund has filed a Form 13G on Cytokinetics, Inc. (NASDAQ:CYTK), one of its top-10 holdings at the end of 2015.
Hedge Funds Are Buying Cytokinetics, Inc. (CYTK)
Before we spend many hours researching a company, we'd like to analyze what hedge funds and billionaire investors think of the stock first.
Cytokinetics, Inc. (CYTK) Conference Call Transcript – Expansion of Collaboration Agreement with Astellas
Below is the Cytokinetics, Inc.
New Changes in SAC Capital’s 13F Portfolio: Annies Inc (BNNY), Cytokinetics, Inc. (CYTK) And Other
In another round of filings with the Securities and Exchange Commission, Steven Cohen and his fund, SAC Capital Advisors, have disclosed 4 new moves: reductions in the ownership...
Mark Lampert, Biotechnology Value Fund Up Stake In Cytokinetics, Inc. (CYTK), Reduce Exposure To Regado Biosciences Inc (RGDO)
Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK).
Hedge Funds Are Selling BioDelivery Sciences International, Inc. (BDSI)
At the moment, there are many indicators market participants can use to watch their holdings. Two of the most under-the-radar are hedge fund and insider trading activity.
This Metric Says You Are Smart to Buy Amicus Therapeutics, Inc. (FOLD)
Now, according to many investors, hedge funds are assumed to be overrated, outdated investment tools of an era lost to time.
Aegerion Pharmaceuticals, Inc. (AEGR): Cheers and Jeers for Amgen, Inc. (AMGN)’s Pipeline
Just after the successful acquisition of Onyx Pharmaceuticals and positive results on AMG-145, a cholesterol-lowering experimental drug, Amgen, Inc.
Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): Digging Deeper Into This Heart Failure Drug’s Miss
Before the market opened last Tuesday, Cytokinetics, Inc. (NASDAQ:CYTK) and Amgen, Inc.
Astex Pharmaceuticals, Inc. (ASTX), GlaxoSmithKline plc (ADR) (GSK), Cytokinetics, Inc. (CYTK): Last Week in Biotech
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
MiMedx Group Inc (MDXG), Cytokinetics, Inc. (CYTK), Amgen, Inc. (AMGN): A Trio of Horrendous Health-Care Stocks This Week
College football arrived in a big way over the past week or so, with plenty of big plays already.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
In the eyes of many investors, hedge funds are viewed as overrated, old investment vehicles of an era lost to time.
What Hedge Funds Think About ArQule, Inc. (ARQL)
In the 21st century investor’s toolkit, there are many metrics shareholders can use to monitor stocks.
Celgene Corporation (CELG), Cytokinetics, Inc. (CYTK), Astex Pharmaceuticals, Inc. (ASTX): Is the Biotech Bubble About to Burst?
"Bubble" can be a provocative word in investing circles. Think of all that comes to mind when you hear it -- perhaps other words like over-hyped, overvalued, risky, etc.
What’s a Smart Cytokinetics, Inc. (CYTK) Investor To Do?
In the eyes of many of your peers, hedge funds are seen as useless, old investment tools of a forgotten age.
Clovis Oncology Inc (CLVS), ACADIA Pharmaceuticals Inc. (ACAD): Healthcare Companies to Watch Out For
Healthcare is the most happening industry these days with new drugs on the line and investors injecting cash into companies with greater speculative growth.
Cytokinetics, Inc. (CYTK), Exelixis, Inc. (EXEL): Three Small Cap Biotech Stocks with Great Potential
Small cap stocks are a bit riskier, but offer more growth than the stable large cap ones. The biotech sector in U.S.
Celldex Therapeutics, Inc. (CLDX), Cytokinetics, Inc. (CYTK): Are These Top Biotech Performers Still Worth Buying?
Only a handful of stocks have gained 200% in 2013, and five of those stocks are in the biotechnology industry.
OncoGenex Pharmaceuticals Inc (OGXI): Are Hedge Funds Right About This Stock?
To the average investor, there are many gauges shareholders can use to monitor stocks. Two of the most underrated are hedge fund and insider trading movement.
Cytokinetics, Inc. (CYTK): Hedge Funds Are Bullish and Insiders Are Bearish, What Should You Do?
Cytokinetics, Inc. (NASDAQ:CYTK) was in 8 hedge funds' portfolio at the end of March.
Hedge Funds Are Crazy About Cytokinetics, Inc. (CYTK)
Is Cytokinetics, Inc. (NASDAQ:CYTK) the right pick for your portfolio? Prominent investors are in a bullish mood.
Hedge Funds Are Buying Amicus Therapeutics, Inc. (FOLD)
Amicus Therapeutics, Inc. (NASDAQ:FOLD) was in 12 hedge funds' portfolio at the end of March.
Is BioDelivery Sciences International, Inc. (BDSI) Going to Burn These Hedge Funds?
BioDelivery Sciences International, Inc.
Pain Therapeutics, Inc. (PTIE): Are Hedge Funds Right About This Stock?
Is Pain Therapeutics, Inc. (NASDAQ:PTIE) a buy, sell, or hold? The smart money is in a bearish mood.
Amgen, Inc. (AMGN), Cytokinetics, Inc. (CYTK): A New Approach to Treating a Broken Heart
A failing heart is a lot like a glass Heinz Ketchup bottle. Squeezing the bottle isn't very efficient, so you smack that strategically placed '57,' and still no condiment. ...
Hedge Funds Aren’t Crazy About Cytokinetics, Inc. (CYTK) Anymore
In today’s marketplace, there are a multitude of indicators market participants can use to analyze their holdings.
Amicus Therapeutics, Inc. (FOLD): Are Hedge Funds Right About This Stock?
Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) a marvelous investment today? Money managers are becoming less confident.
Enzon Pharmaceuticals, Inc. (ENZN): Are Hedge Funds Right About This Stock?
Is Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN) a buy, sell, or hold? The best stock pickers are taking a bearish view.
Zynga Inc (ZNGA), Cytokinetics, Inc. (CYTK), and More: 3 Stocks That Blew the Market Away
Every week, I take a look at three companies that beat market expectations, since I believe that it's the biggest factor in a stock beating the market.
